embody vs altRx vs Medvi: Our Top Three, One Table
Last updated: Aug 28, 2026
We may earn a commission from links on this page - it never affects our rankings (how we stay objective).
Here’s the short version
Thirty dollars separates these three, and none of them asks for a commitment - so this comparison is really about what each adds on top of the same compounded semaglutide. embody keeps it lean: $69 flat at every dose, free 1-2 day shipping, and a full refund if a provider doesn't approve you. altRx charges $89 and is the only one with a brand-name shelf - Ozempic, Zepbound and Wegovy at published cash prices - plus Buy Now, Pay Later. Medvi's $99 promo is all-inclusive with video visits, a free dietician and care coaching, backed by the strongest review record of the three: 4.4 across 14,372 Trustpilot reviews.
embody vs altRx vs Medvi: side by side
Real published prices and terms - the differences that actually decide this matchup.
| embody | altRx | Medvi | |
|---|---|---|---|
| Semaglutide | $69/mo, flat at every dose | $89/mo (reg. $199), flat at every dose | $99/mo promo (reg. $199), all-inclusive |
| Tirzepatide | $119/mo | $149/mo (reg. $299) | $166/mo promo (reg. $299) |
| Billing & commitment | Monthly - no commitment, cancel anytime | Monthly - pause or cancel anytime; Buy Now, Pay Later | Monthly, all-inclusive - no surprise charges; HSA/FSA approved |
| Shipping | Free 1-2 day, tracked & insured | Free nationwide delivery | Free shipping |
| Support | Licensed doctors, medical director & nursing team | Licensed provider review (physician, PA, or NP) | Video visits + free dietician & care coaching |
| Guarantee / refund | Full refund if you're not approved | - | - |
| Standout | LegitScript-certified; 503A pharmacies | Brand-name shelf: Ozempic $1,149 · Zepbound $1,249 · Wegovy $1,579 | 4.4 on Trustpilot across 14,372 reviews |
Our verdict
All three bill monthly with no prepaid term, so the price gap is the honest starting point: $69, $89, $99. Pay the minimum and move fast: embody - cheapest here, quickest shipping, and the refund-if-not-approved policy removes the main risk of trying. Think brand-name Ozempic or Zepbound might be in your future: altRx - it's the only one of the three where that switch happens without changing providers, and BNPL softens the brand prices. Want a person in the loop - video visits, a dietician, someone to call: Medvi, and its 14,372-review Trustpilot record says the support model works. There's no legitimacy gap to worry about: all three run licensed-provider review and dispense through regulated pharmacies.
embody vs altRx vs Medvi: FAQs
Which is cheapest: embody, altRx or Medvi?
For compounded semaglutide: embody at $69/month flat (regularly $79), then altRx at $89/month promotional (regularly $199), then Medvi at $99/month promotional (regularly $199) all-inclusive. For tirzepatide: embody $119, altRx $149 (regularly $299), Medvi $166 promotional (regularly $299). All three bill monthly with no prepaid commitment.
Which has the best customer reviews?
Medvi has the strongest verified review record of the three - 4.4 on Trustpilot across 14,372 reviews, with support and communication the recurring themes. embody holds 3.8 across 4,956 reviews. Current ratings for each provider are shown on their cards above.
Can I get brand-name Ozempic, Zepbound or Wegovy from any of them?
Only altRx. Alongside its $89/month compounded semaglutide it publishes cash prices for brand-name medication - Ozempic at $1,149, Zepbound at $1,249 and Wegovy at $1,579 per month - with Buy Now, Pay Later available. embody and Medvi focus on compounded GLP-1s.
Do any of these require a long-term commitment?
No - all three bill month to month. embody adds a full refund if a licensed provider doesn't approve you for treatment, altRx lets you pause or cancel anytime, and Medvi's all-inclusive rate is HSA/FSA approved with no surprise charges.
Break it down two at a time
The head-to-head comparisons between these providers.
Sources & medical references
Treatment facts on this page are grounded in regulatory guidance and peer-reviewed research. Pricing and plan details come from each provider's published information. This content is for information only and is not medical advice - always consult a licensed clinician before starting treatment.
- 1.Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1 trial) - New England Journal of Medicine, 2021
- 2.Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1 trial) - New England Journal of Medicine, 2022
- 3.FDA Approves New Drug Treatment for Chronic Weight Management (semaglutide / Wegovy) - U.S. Food & Drug Administration, 2021
- 4.FDA Approves New Medication for Chronic Weight Management (tirzepatide / Zepbound) - U.S. Food & Drug Administration, 2023
- 5.FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss - U.S. Food & Drug Administration
- 6.Human Drug Compounding (503A pharmacy standards) - U.S. Food & Drug Administration
- 7.Semaglutide Injection - drug information - MedlinePlus, U.S. National Library of Medicine (NIH)